• Home
  • Publications
  • Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial

Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial

Authors:

  • Khurum H. Khan; David Cunningham; Benjamin Werner; Georgios Vlachogiannis; Inmaculada Spiteri; Timon Heide; Javier Fernandez Mateos; Alexandra Vatsiou; Andrea Lampis; Mahnaz Darvish Damavandi; Hazel Lote; Ian Said Huntingford; Somaieh Hedayat; Ian Chau; Nina Tunariu; Giulia Mentrasti; Francesco Trevisani; Sheela Rao; Gayathri Anandappa ; David Watkins; Naureen Starling; Janet Thomas; Clare Peckitt; Nasir Khan; Massimo Rugge; Ruwaida Begum; Blanka Hezelova; Annette Bryant; Thomas Jones; Paula Proszek; Matteo Fassan; Jens C. Hahne; Michael Hubank; Chiara Braconi;,
  • Sottoriva A.,
  • Valeri N.

Abstract:

Sequential profiling of plasma cell-free DNA (cfDNA) holds immense promise for early detection of patient progression. However, how to exploit the predictive power of cfDNA as a liquid biopsy in the clinic remains unclear. RAS pathway aberrations can be tracked in cfDNA to monitor resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer. In this prospective phase II clinical trial of single-agent cetuximab in RAS wild-type patients, we combine genomic profiling of serial cfDNA and matched sequential tissue biopsies with imaging and mathematical modeling of cancer evolution. We show that a significant proportion of patients defined as RAS wild-type based on diagnostic tissue analysis harbor aberrations in the RAS pathway in pretreatment cfDNA and, in fact, do not benefit from EGFR inhibition. We demonstrate that primary and acquired resistance to cetuximab are often of polyclonal nature, and these dynamics can be observed in tissue and plasma. Furthermore, evolutionary modeling combined with frequent serial sampling of cfDNA allows prediction of the expected time to treatment failure in individual patients. This study demonstrates how integrating frequently sampled longitudinal liquid biopsies with a mathematical framework of tumor evolution allows individualized quantitative forecasting of progression, providing novel opportunities for adaptive personalized therapies.

  • Facebook
  • Twitter
  • LinkedIn
  • Email

Links: